Wells Fargo & Company Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $37.00

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price increased by Wells Fargo & Company from $35.00 to $37.00 in a report published on Monday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the company. HC […]

Leave a Reply

Your email address will not be published.

Previous post Susquehanna Increases Expedia Group (NASDAQ:EXPE) Price Target to $145.00
Next post HC Wainwright Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $55.00